title: A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.
abstract: The ideal dengue vaccine will provide protection against all serotypes of dengue virus and will be economical and uncomplicated in its administration. To determine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to induce a suitable neutralizing antibody response, a placebo-controlled clinical trial was performed in 48 healthy adults who received 2 doses of vaccine or placebo administered 12 months apart. Evaluation of safety, vaccine viremia, and neutralizing antibody response after each dose indicated that the first dose of vaccine was capable of preventing infection with the second dose, thus indicating that multiple doses are unnecessary.
  
  
  BACKGROUND
  NCT01782300.
authors.affiliation: Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
authors.forename: Anna P
authors.initials: AP
authors.lastname: Durbin
authors.affiliation: Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
authors.forename: Beth D
authors.initials: BD
authors.lastname: Kirkpatrick
authors.affiliation: Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
authors.forename: Kristen K
authors.initials: KK
authors.lastname: Pierce
authors.affiliation: Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
authors.forename: Marya P
authors.initials: MP
authors.lastname: Carmolli
authors.affiliation: Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
authors.forename: Cecilia M
authors.initials: CM
authors.lastname: Tibery
authors.affiliation: Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
authors.forename: Palmtama L
authors.initials: PL
authors.lastname: Grier
authors.affiliation: Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
authors.forename: Noreen
authors.initials: N
authors.lastname: Hynes
authors.affiliation: Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
authors.forename: Kari
authors.initials: K
authors.lastname: Opert
authors.affiliation: Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
authors.forename: Adrienne P
authors.initials: AP
authors.lastname: Jarvis
authors.affiliation: Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
authors.forename: Beulah P
authors.initials: BP
authors.lastname: Sabundayo
authors.affiliation: Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
authors.forename: Benjamin D
authors.initials: BD
authors.lastname: McElvany
authors.affiliation: Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
authors.forename: Eli A
authors.initials: EA
authors.lastname: Sendra
authors.affiliation: Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
authors.forename: Catherine J
authors.initials: CJ
authors.lastname: Larsson
authors.affiliation: Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
authors.forename: Matthew
authors.initials: M
authors.lastname: Jo
authors.affiliation: Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
authors.forename: Janece M
authors.initials: JM
authors.lastname: Lovchik
authors.affiliation: Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.
authors.forename: Catherine J
authors.initials: CJ
authors.lastname: Luke
authors.affiliation: Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
authors.forename: Mary C
authors.initials: MC
authors.lastname: Walsh
authors.affiliation: Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
authors.forename: Ellen A
authors.initials: EA
authors.lastname: Fraser
authors.affiliation: Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.
authors.forename: Kanta
authors.initials: K
authors.lastname: Subbarao
authors.affiliation: Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.
authors.forename: Stephen S
authors.initials: SS
authors.lastname: Whitehead
mesh_terms: D000328:Adult; D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D003715:Dengue / Q000276:immunology / Q000517:prevention & control*; D053059:Dengue Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D004311:Double-Blind Method; D006801:Humans; D007115:Immunization Schedule; D054579:National Institute of Allergy and Infectious Diseases (U.S.); D010919:Placebos / Q000008:administration & dosage; D014481:United States; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D053059:Dengue Vaccines; D010919:Placebos; D014613:Vaccines, Attenuated
keywords: clinical trial; dengue vaccine; live attenuated tetravalent